Abstract 754P
Background
Ubamatamab (REGN4018) is a mucin16 (MUC16) x CD3 bispecific antibody. Cemiplimab, an anti-PD-1 antibody, enhanced its activity in preclinical studies. In phase 1 (NCT03564340), ubamatamab monotherapy resulted in an acceptable safety profile and durable responses. We now present ubamatamab combined with cemiplimab dose escalation results.
Methods
Patients (pts) with recurrent platinum-experienced ovarian cancer (OC) received weekly intravenous (IV) ubamatamab at a dose range of 1–450 mg after initial step-up dosing. Cemiplimab 350 mg IV every 3 weeks was added beginning Day 29–36. Dose escalation initially followed a modified 3+3 design, then Bayesian optimal interval design. Primary endpoints were safety and PK. Secondary endpoints included confirmed objective response rate (ORR), Kaplan-Meier estimated duration of response (DoR) and progression-free survival (PFS) (RECIST 1.1), and CA125 response (GCIG).
Results
35 pts were enrolled, 29 (82.9%) received ≥1 dose of cemiplimab. Median number of prior therapies was 5 (range 1−10). Median duration of ubamatamab and cemiplimab exposure was 11 (range 2−75) and 12 (3−69) weeks, respectively. The most common treatment-emergent adverse events (TEAE) were pain (82.9%) and cytokine release syndrome (68.6%, all Grade [G] 1/2). The most common G≥3 TEAE were anaemia (25.7%), pain (20.0%) and neutropaenia (11.4%, 1 dose-limiting toxicity [DLT], 60 mg). Ubamatamab 1–250 mg weekly with cemiplimab was tolerable. In the highest dose cohort (450 mg), haemophagocytic lymphohistiocytosis (G4, DLT) was observed. Objective responses were observed at ubamatamab doses 10–250 mg (n=25). In 22 of these pts receiving ≥1 dose of cemiplimab, ORR was 18.2% (95% CI: 5.2–40.3), median DoR 8.3 months (4.2–not estimable), CA125 response rate 22.7% (7.8–45.4) and 6-month PFS 47.6% (25.7–66.7). Two pts with target lesion growth (+17%, +31%) before adding cemiplimab to ubamatamab had subsequent partial responses. Ubamatamab PK was not impacted by cemiplimab.
Conclusions
In pts with heavily pretreated OC, an acceptable safety profile and durable responses were observed with ubamatamab + cemiplimab. A randomised phase 2 expansion of ubamatamab +/- cemiplimab is ongoing.
Clinical trial identification
NCT03564340.
Editorial acknowledgement
Writing assistance was provided by Brian Head, PhD, of Regeneron Pharmaceuticals, Inc.
Legal entity responsible for the study
Regeneron Pharmaceuticals, Inc.
Funding
Regeneron Pharmaceuticals, Inc.
Disclosure
R.E. O'Cearbhaill: Financial Interests, Personal, Other, Personal Fees: Bayer, Curio, Fresenius Kabi, Immunogen, MJH, Regeneron, Seattle Genetics, and Tesaro/GSK; Financial Interests, Personal, Other, Travel: Hitech Health ; Financial Interests, Personal, Advisory Board: GSK; Non-Financial Interests, Personal, Steering Committee Member: PRIMA, Moonstone (Tesaro/GSK) and DUO-O (AstraZeneca) studies; Non-Financial Interests, Personal, Advisory Role: Carina Biotech; Financial Interests, Institutional, Research Funding: AbbVie/StemCentrx, Atara Biotherapeutics, Bayer/Celgene/Juno, Genentech, Genmab/Seagen Therapeutics, Gynecologic Oncology Foundation , Kite Pharma, Ludwig Cancer Institute, Marker Therapeutics, Merck, Regeneron, Sellas Therapeutics, Syndax Pharmaceuticals, ; Financial Interests, Personal, Other, NRG representative: ComboMATCH study. K.N. Moore: Financial Interests, Personal, Advisory Board, Personal fees (consulting and/or advisory boards): Alkemeres, Aravive, AstraZeneca, Blueprint Pharma, Caris, Eisai, Elevar, Genentech/Roche, GSK/Tesaro, Hengrui, IMab, Immunogen, Inxmed, Iovance, Lilly, Mereo, Mersana, Myriad, Novartis, Novocure, Tarveda, VBL Therapeutics and Verastem; Financial Interests, Institutional, Research Funding: AbbVie, Artios, AstraZeneca, Daiichi Sankyo, Genentech/Roche, GSK/Tesaro, Immunogen, Lilly, Merck, Mereo, Novocure, PTC Therapeutics and Regeneron. O. Yeku: Financial Interests, Personal, Advisory Board: Celldex, GIMV NV, hC Bioscience and TigaTx. J.F. Liu: Financial Interests, Personal, Advisory Board, Personal fees (consulting and/or advisory boards): AstraZeneca, Clovis Oncology, Eisai, EpsilaBio, Genentech/Roche, GSK and Regeneron Pharmaceuticals, Inc.; Financial Interests, Institutional, Research Funding: 2X Oncology, Aravive, Arch Oncology, AstraZeneca, Bristol Myers Squibb, Clovis Oncology, CytomX Therapeutics, GSK, Regeneron, Surface Oncology, Tesaro, Vigeo Therapeutics and Zentalis. S. Bouberhan: Financial Interests, Personal, Speaker, Consultant, Advisor: ImmunoGen. E.P. Hamilton: Financial Interests, Institutional, Research Grant: Regeneron, AbbVie, Acerta Pharma, ADC Therapeutics, Akesobio Australia, Amgen, Aravive, ArQule, Arvinas, AstraZeneca, AtlasMedX, Black Diamond, Boehringer Ingelheim, Clovis, Compugen, Curis, CytomX, Dana Farber Cancer Inst, Daiichi Sankyo, Deciphera, eFFE; Financial Interests, Institutional, Speaker, Consultant, Advisor: Arcus, Arvinas, AstraZeneca, Black Diamond, Boehringer Ingelheim, CytomX, Daiichi Sankyo, Dantari, Deciphera Pharmaceuticals, Eisai, H3 Biomedicine, iTeos, Janssen, Lilly, Loxo, Merck, Mersana, Novartis, Pfizer, Puma Biotechnology, Relay Therapeutics, Roc. S. Yoo, S. Govindraj, J. Brouwer-Visser, M. Peterman, T. Schmidt, B. Barnes, P. Madia, M. Zhu, T.S. Uldrick, E.A. Miller: Financial Interests, Personal, Full or part-time Employment: Regeneron Pharmaceuticals, Inc.; Financial Interests, Personal, Stocks/Shares: Regeneron Pharmaceuticals, Inc. D. O'Malley: Financial Interests, Personal, Research Funding: AbbVie, Agenus, Amgen, AstraZeneca, Celsion Corp, Clovis, Corcept Therapeutics, Eisai, GOG Foundation , Immunogen, Iovance, Janssen/Johnson & Johnson, Mersana, Novocure and Genentech/Roche, Regeneron, SDP Oncology (BBI), Seagen and Tesaro/GSK, Ajinomoto Inc., Array Biopharma, Bristol Myers Squibb Co., Cerulean Pharma, EMD Serono, Ergomed, Inc. Research, Inc., inVentiv Health Clinical PRA Intl, Ludwig Cancer Research, Merck and GenMab, New Mexico Cancer Care Alliance, Serono Inc., Stemcentrx, Inc; Financial Interests, Personal, Advisory Board, Personal fees (consulting and/or advisory boards): Ambry, Arquer Diagnostics, Elevar, INXMED, Myriad Genetics, Novartis, Rubis, Roche Diagnostics MSA, Sorrento, Takeda, Tarveda and Toray, AbbVie, Agenus, Amgen, AstraZeneca, Celsion Corp, Clovis, Corcept Therapeutics, Eisai, GOG Foundation, Immunogen, Iovance, Janssen/Johnson & Johnson, Mersana, Novocure and Genentech/Roche, Regeneron, SDP Oncology (BBI), Seagen and Tesaro/GSK. All other authors have declared no conflicts of interest.
Resources from the same session
628P - Immunotherapy in mismatch repair-deficient metastatic colorectal cancer: Long-term outcome and novel predictive markers
Presenter: Amos Stemmer
Session: Poster session 11
629P - First results of the french prospective cohort of colorectal cancers with microsatellite instability (COLOMIN2)
Presenter: David Tougeron
Session: Poster session 11
630P - Determining a prognostic score using imaging to assess the benefit of combo anti-PD1 + anti-CTL4 vs anti-PD1 in patients with metastatic MSI/dMMR colorectal cancer (mCRC MSI)
Presenter: Remy Barbe
Session: Poster session 11
631P - Using the unique somatic mutation profile of POLE loss of proof-reading mutation helps in selection of patients who may benefit from immunotherapy
Presenter: Giulia Maddalena
Session: Poster session 11
632P - Predictive value of C-reactive protein (CRP) in microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) patients given first-line alternating short-course oxaliplatin-based chemotherapy (FLOX) and nivolumab
Presenter: Sebastian Meltzer
Session: Poster session 11
633P - Genomic alterations in SPEN predict outcome of immune checkpoint therapy in gastrointestinal cancer
Presenter: Changxiong Wu
Session: Poster session 11
634P - The ave-rec phase II trial of PD-L1/PD-1 blockade with avelumab plus chemoradiotherapy for resectable ESMO high risk rectal cancers
Presenter: Michael Michael
Session: Poster session 11
635P - Avelumab (AVE) combined with cetuximab (CET) and irinotecan (IRI) for the treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): The AVETUXIRI phase II study
Presenter: Marc van den Eynde
Session: Poster session 11